Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX).

Affiliation auteurs!!!! Error affiliation !!!!
TitreGemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracile plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX).
Type de publicationJournal Article
Year of Publication2018
AuteursTaieb J, Rinaldi Y, Pointet A-L, Barbier E, Khemissa F, Gratet A, Miglianico L, Laharie-Mineur H, Bouhier-Leporrier K, Ghiringhelli F, Bidault AThirot, Texereau P, Coriat R, Terrebonne E, Gouttebel M-C, Malka D, Lepage C, Bachet J-B
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume36
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2018.36.15_suppl.4107